Actualités dans la prise en charge de l’anémie Congrès mondial de Néphrologie 2009

Bright, 1836, Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine, Guys Hosp Rep, 1, 338 Coresh, 2003, Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey, Am J Kidney Dis, 41, 1, 10.1053/ajkd.2003.50007 Fink, 1997, Use of erythropoietin before the initiation of dialysis and its impact on mortality, Am J Kidney Dis, 29, 541 Portolés, 1997, Cardiovascular effects of recombinant human erythopoietin in predialysis patients, Am J Kidney Dis, 29, 541, 10.1016/S0272-6386(97)90335-8 Jones, 2004, Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis, Kidney Int, 65, 757, 10.1111/j.1523-1755.2004.00450.x European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;15 (Suppl 5):1-50. NKF K/DOQI Guidelines 2000. http://www.kidney.org/professionals/kdoqi/guidelines_updates/doqi_uptoc.html Rossert, 2005, Erythropoetin receptors: their role beyond erythropoiesis, Nephrol Dial Transplant, 20, 1025, 10.1093/ndt/gfh800 Jelkmann, 2008, The erythropoietin receptor in normal and cancer tissues, Crit Rev Oncol Hematol, 67, 39, 10.1016/j.critrevonc.2008.03.006 Brines, 2004, Erythropoietin mediates protection throught an erythropoietin and common beta-subunit heteroreceptor, Proc Natl Acad Sci USA, 101, 14907, 10.1073/pnas.0406491101 Parsa, 2003, A novel protective effect of erytropoietin in the infracted heart, J Clin Invest, 112, 999, 10.1172/JCI18200 Coleman, 2006, Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities, Proc Natl Acad Sci USA, 13, 5965, 10.1073/pnas.0601377103 Corwin, 2007, Efficacy and safety of epoetin alpha in critically ill patients, N Engl J Med, 357, 965, 10.1056/NEJMoa071533 Brines, 2008, Nonerythropoietic, tissue protective peptide derived from the tertiary structure of erythropoietin, Proc Natl Acad Sci USA, 105, 10925, 10.1073/pnas.0805594105 Erbayraktar, 2009, Non erythropoietic tissue protective compounds are highly effective facilitators of wound healing, Mol Med, 15, 235, 10.2119/molmed.2009.00051 Besarab, 1998, The effects of normal as compared with low hematocit values in patients with cardiac disease who are receiving hemodialysis and epoetin, NEJM, 339, 584, 10.1056/NEJM199808273390903 Drüeke, 2006, Noramalization of hemoglobin level in patients with chronic kidney disease and anemia, N Engl J Med, 355, 2071, 10.1056/NEJMoa062276 Singh, 2006, Correction of anemia with epoetin alfa in chronic kidney disease, N Engl J Med, 355, 2085, 10.1056/NEJMoa065485 Locatelli, 2009, Anaemia management in patients with chronic kidney disease: a position statement by the anaemia working group of European renal best practice (ERBP), Nephrol Dial Transplant, 24, 348, 10.1093/ndt/gfn653 Lakson, 2003, Effect of variability in anemia management on hemoglobin outcomes in ESRD, Am J Kindey Dis, 41, 111, 10.1053/ajkd.2003.50030 Fishbane, 2005, Hemoglobine cycling in hemodialyis patients treated with recombinant human erythropoietin, Kidney Int, 68, 1337, 10.1111/j.1523-1755.2005.00532.x Ebben, 2006, Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations, Clin J Am Soc Nephrol, 1, 1205, 10.2215/CJN.01110306 Gilbertson, 2006, The effect of hemoglobin (Hb) variability and trends on mortality, J Am Soc Nephrol, 17, 582A Feldman, 2006, Hemoglobin variability an mortality among hemodialysis patients, J Am Soc Nephrol, 17, 583A Boudville, 2009, Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality, Clin J Am Soc Nephrol, 4, 1176, 10.2215/CJN.04920908 Focus sur les biosimilaires et actualités dans le cancer du colon métastatique. Profession cancérologue 2009;N°16 cahier 2:5. Bouchet, 2009, Position statements regarding usage of biosimilars of epoetins. Position paper of the Société de Néphrologie, Société Francophone de Dialyse, and Société de Néphrologie Pédiatrique, Nephrol Ther, 5, 61, 10.1016/j.nephro.2008.10.006 Casadevall, 2002, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin, N Engl J Med, 346, 469, 10.1056/NEJMoa011931 Kirkov, 2008, Evaluation of the pharmacokinetics of two recombinant human erythropoetin preparations:epoetin zeta and epoetin alfa. 1st Communication: a monocentric open randomized, single dose, two-period crossover trial in healthy volunteers, Arzneimittelforschung, 58, 215 Kirkov, 2008, Evaluation of the pharmacokinetics of two recombinant human erythropoetin preparations:epoetin zeta and epoetin alfa. 2nd Communication: a monocentric double blind, randomized, single dose, three-period crossover trial in healthy volunteers, Arzneimittelforschung, 58, 220 Krivoshiev, 2008, Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia, Current Med Res Opin, 4, 1407, 10.1185/030079908X297402 Wizemann, 2008, Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment, Cur Med Res Opin, 24, 625, 10.1185/030079908X273264 Baldamus, 2008, Long-term safety and tolerability of epoetin zeta, administered intravenously for maintenance treatment of renal anemia, Adv Ther, 25, 1215, 10.1007/s12325-008-0111-1 Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Plješa S, Wolf M et al. Therapeutic Equivalence of Epoetin Zeta and Alfa, Administered Subcutaneously, for Maintenance Treatment of Renal Anemia. Adv Ther (2010) 27:in press.